Further promising data seen with Biogen Alzheimer's drug: study

(Reuters) - Gradually increasing the dose of Biogen Inc's experimental Alzheimer's disease drug appeared to cause less risk of brain swelling than fixed doses, according to interim 12-month results from a small study released on Thursday.